

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the 10th Annual General Meeting of the Members of Satnam Medical Agencies Private Limited will be held at the Registered Office of the Company at 1704, Pvt Shop No.-1, F/F Bhagirathi Palace, Chandni Chowk, New Delhi-110006 on Friday, 30th day of September, 2022 at 11:30 A.M. to transact the following business:-

ORDINARY BUSINESS

1. Adoption of Financial Statements:-

To receive, consider and adopt:

- a) The Audited standalone Financial statements of the Company for the year ended 31st March, 2022 including Audited Balance Sheet as at 31st March, 2022 and the Statement of the Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon, and ,
- b) To ratify the appointment of M/s ARUN PRAKASH PANJRATH & ASSOCIATES., Chartered Accountants, New Delhi, as Statutory Auditors of the Company and to fix their remuneration ,and in this regard to consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 139 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and pursuant to the recommendations of the Board of Directors, appointment of M/s ARUN PRAKASH PANJRATH & ASSOCIATES., Chartered Accountants, as the Statutory Auditor of the Company, is be and hereby ratified to hold office from conclusion of this meeting till the conclusion of the next Annual General Meeting on a remuneration to be fixed by the Board of Directors of the Company,

1. Any Other matter with the permission of the chair.

For and on Behalf of
SATNAM MEDICAL AGENCIES PRIVATE LIMITED



NIRMAL JAIN

Director

DIN: 05276862

August, 9th, 2022
New Delhi

NOTES:

1. A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of himself and the proxy need not be a member of the company.
2. Proxies, in order to be effective, should be duly completed, stamped and signed and must be deposited at the registered office of the Company not less than 48 hours before the commencement of the meeting.
3. Pursuant to provisions of section 105 of the Companies Act, 2013, read with the applicable rules thereon, a person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total Share Capital of the Company carrying voting rights, may appoint a single person as proxy, who shall not act as a proxy for any other member.
4. Corporate members intending to send their authorized representatives to attend the meeting are requested to send to the company a certified copy of the Board resolution authorizing their representative to attend and vote on their behalf at the meeting

**For and on Behalf of
SATNAM MEDICAL AGENCIES PRIVATE LIMITED**



**NITIN JAIN
Director
DIN: 05276862**

**August, 9th, 2022
New Delhi**

Form No. MGT-11
Proxy Form

*[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies
(Management and Administration) Rules, 2014]*

CIN: U24232DL2013PTC250040

Name of the Company: SATNAM MEDICAL AGENCIES PRIVATE LIMITED

**Registered office: 1704, PVT SHOP NO.-1, F/F BHAGIRATHI PALACE CHANDNI CHOWK NEW
DELHI-110006**

Name of the Member (s):

Registered Address:

E-mail Id:

Folio No/ Client Id:

DP ID: N.A.

I, being the Shareholder, holding....., holding shares of the above named Company, hereby
appoint

1. Name:
2. Address:
3. E-mail Id:
4. Signature: _____, or failing him

as our proxy to attend and vote (on a poll) for us and on our behalf at the 9th Annual General
Meeting of the Company, to be held on the 30th day of September, 2022 At 11:30 am at the
Registered office of the Company at: 1704, Pvt Shop No.-1, F/F Bhagirathi Palace, Chandani Chowk,
New Delhi-110006 and at any adjournment thereof in respect of such resolutions as are indicated
below:

S. No.	Resolution	For	Against
	Ordinary Business		
1.	To receive, consider and adopt the Financial Statement of the Company for the year ended 31st March, 2022 including Audited Balance Sheet as at 31st March, 2022 and the Statement of the Profit & Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon		
2.	To ratify the appointment of M/s ARUN PRAKASH PANJRATH & ASSOCIATES, Chartered Accountants, New Delhi, as Statutory Auditors of the Company and to fix their remuneration for the financial year ending 31st March, 2022		

Signed this..... day of -----, 2022

Signature of Shareholder: _____

Signature of Proxy holder(s): _____

**Affix
Revenue
Stamp**

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

DIRECTORS REPORT

To The Members Satnam Medical Agencies Private Limited

1704, PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDNI CHOWK NEW DELHI-110006.

Your Directors have pleasure in presenting herewith their 10th Director Report on the business and operation of the Company together with the Audited Statements of Accounts of the Company for the year ended on 31st March, 2022.

1. **FINANCIAL SUMMARY OF THE COMPANY:-** The company's financial performance during the year 2021-22 as compared to previous year 2020-21 is summarised below:-

PARTICULARS	FY 2021- 2022	FY 2020-2021
Income for the year	43,70,75,666.00	1,53,65,178.00
Other Income	9,32,415.00	48,391.00
Expenditure for the year excluding Depreciation and Amortization Expenditure	43,23,41,241.00	1,46,33,459.00
Profit or Loss before Depreciation and Amortization Expenditure	56,66,850.00	7,80,110.00
Less: Depreciation and Amortization Expenses	5,11,206.00	4,93,732.00
Profit or Loss after Depreciation and Amortization Expenses but before Tax	51,55,644.00	2,86,378.00
Less: Current Tax	13,74,924.00	89,584.00
Add/(Less):-Deferred Tax	(34456.00)	(15,124.00)
Profit or Loss After Tax	38,15,176.00	2,11,918.00

FINANCIAL HIGHLIGHTS: - During year under review company has grown the business and we are hopeful of generating more revenue during next year.

2. **DIVIDEND:-**

In view of the future growth opportunities, your Directors do not recommend any dividend during the year under review and have retained the profit for the purpose of expansion.

3. **RESERVES:-**

The Company has not declared any dividend and retained all the profits and share premium was transferred under the head Reserve and Surplus.

4. **BRIEF DESCRIPTION OF THE COMPANY'S PERFORMANCE DURING THE YEAR:-**

Our Company, following all the necessary applicable ethical considerations and best sustainability business model under the current legal framework of the country, is leading strategically thus continuously growing its business operations as desired. All its functions are holistically benefitting all the involved stakeholders without jeopardizing the interests of one at the cost of other. The company's operations are running to achieve the desirable economic ends with all the socially acceptable means. This is very much in consonance with the current business needs of the company and operational efficiency along with future growth.

5. **CHANGE IN THE NATURE OF BUSINESS, IF ANY:-**

There was no change in the Nature of the Business during the period under review and the company continues to do the business activity as per previous year business strategy.

6. **MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:-**

No Material changes and commitments affecting the financial position of the Company occurred between the ends of the Financial Years to which this Financial Statements relate on the date of this report.

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

7. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:-

There Were No Significant and Material Orders passed by the regulators Or Courts or Tribunals Impacting the Going Concern Status And Company's Operations In Future Details In Respect Of Adequacy of Internal Financial Controls with Reference to the Financial Statements.

8. DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANIES:-

The Company has one wholly owned Company **IBERIA SKINBRANDS LIMITED** with 100% shareholding. The same has been disclosed in AOC-1.

9. DEPOSITS:-

The Company has neither accepted nor renewed any Deposits during the year under review.

10. STATUTORY AUDITORS:-

M/s ARUN PRAKASH PANJRATH AND ASSOCIATES, Chartered Accountant, New Delhi were appointed as statutory Auditors of the company for a period of 5 years. In terms of the first proviso of Section 139 of the Companies Act, 2013, the appointment of the auditor shall be placed for ratification at every Annual General Meeting. Accordingly, the appointment of M/s ARUN PRAKASH PANJRATH AND ASSOCIATES, Chartered Accountant, New Delhi as statutory Auditors of the Company, is placed for ratification by the shareholders. In this regard, the Company has received a certificate to the effect that their Re-appointment if made would fulfill the criteria and the provisions of section 139 and 141 of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014.

11. AUDITORS' REPORT:-

There are no qualifications or adverse remarks in the Statutory Auditors' Report which require any explanation from the Board of Directors.

12. AUDIT COMMITTEE:-

As per Section 177 of the Companies Act, 2013 and Rule 6 and 7 of Companies (Meetings of Board and its Powers) Rules, 2014 constitution of Audit Committee is not applicable to our Company.

13. SHARE CAPITAL:-

Share capital as on **31/03/2021** was 10,37,500/- and share premium amount received on issue of share capital was 65,62,500/-

14. DECLARATION OF INDEPENDENT DIRECTORS:-

The provisions of Section 149 pertaining to the Appointment of Independent Directors do not apply to our Company

15. REPORT ON CORPORATE GOVERNANCE: Not Applicable

16. COST AUDIT: Not Applicable

17. SECRETARIAL AUDIT REPORT: Not Applicable

18. INTERNAL AUDIT & CONTROLS: Not Applicable

19. EXTRACT OF THE ANNUAL RETURN:-

The extract of the annual return in Form No: MGT- 9 shall form part of the Board's report. **(Annexure A)**

20. CORPORATE SOCIAL RESPONSIBILITY INITIATIVES: Not Applicable

21. PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION:-

Pursuant to section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014. Information as per section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 are not applicable on company.

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

22. FOREIGN EXCHANGE EARNINGS / OUTGO:-

The information pertaining to Foreign Exchange Earnings and outgo as required under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is furnished hereunder:

- i) The Foreign Exchange earned during the year is Rs. Nil
- ii) The Foreign Exchange outgo during the year is Rs. Nil

23. DIRECTORS:-

Details of directorship as on 31.03.2021

S.No	Name	Designation
1.	PRAVEEN JAIN	Director
2.	NITIN JAIN	Director

24. NUMBER OF MEETINGS OF THE BOARD OF DIRECTORS:-

A calendar of Meetings is prepared and circulated in advance to the Directors. During the year **5(Five)** Board Meeting were held ended **March 31, 2022**.

The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013. All the board meetings were attended by both the directors.

25. ESTABLISHMENT OF VIGIL MECHANISM (section 177 (10)):- Not Applicable

26. NOMINATION AND REMUNERATION COMMITTEE (Section 178 (1) & (3)):- Not Applicable

27. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:-

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statements.

28. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES UNDER SECTION 188:-

During the year, the Company has entered into transactions with related parties as defined under Section 2(76) of the Companies Act, 2013 which were in the ordinary course of business and on arm's length basis and in accordance with the provisions of the Companies Act, 2013, and there were no transactions with related parties which qualify as material transactions. The details of the related party transactions as required under Accounting Standard -18 are set out in Notes to the financial statements forming part of this Financial Statements. The Disclosure required in Form AOC-2 pursuant to Section 134 (3)(h) read with Rule 8(2) of the Companies (Accounts) Rules, 2014 is enclosed.

29. DIRECTORS RESPONSIBILITY STATEMENT:-

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that—

- a) In the preparation of the annual accounts for financial year ended **31st March, 2022**, the applicable accounting standards have been followed and there is no material departures from the same;
- b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that year;
- c) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) The Directors have prepared the annual accounts for the financial year ended **31st March, 2022** on a going concern basis.

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

- e) The directors, in the case of a listed company, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such system were adequate and operating effectively.

30. THE DETAILS IN RESPECT OF INTERNAL FINANCIAL CONTROL SYSTEM

The Company has in place adequate internal financial controls with reference to financial statements. During the year under review, such controls were tested and no reportable material weaknesses in the design or operation were observed.

31. BUSINESS RESPONSIBILITY REPORTING:- Not applicable

32. DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company is committed to provide a safe and conducive work environment to its employees. During the year under review, no case of sexual harassment was reported.

33. INVESTOR EDUCATION PROTECTION FUND:- - There were no amount which is required to be transferred under IEPF.


34. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR:- Not applicable

35. THE DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:- Not applicable

36. ACKNOWLEDGMENT:-

Your Directors place on record their sincere thanks to the Banks, Central and State Governments for their continuous support and contribution to the company. The Directors also express their gratitude to the Shareholders for the confidence reposed in the Management of the Company.

FOR AND ON BEHALF OF
SATNAM MEDICAL AGENCIES PRIVATE LIMITED



Nitin Jain
Director
DIN: 05276862

August 9th, 2022
New Delhi

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

Annexure -A

Form No. MGT - 9

Extract of Annual Return as on the Financial Year ended on 31st March, 2022 (Pursuant to Section 92 (3) of the Companies Act, 2013 and Rule 12 (1) of the Companies (Management and Administration) Rules, 2014

I. REGISTRATION & OTHER DETAILS:

1.	CIN	U2423DL2013PTC250040
2.	Registration Date	30/03/2013
3.	Name of the Company	SATNAM MEDICAL AGENCIES PRIVATE LIMITED
4.	Category/Sub-category of the Company	Company limited by shares/ Indian Non-Government Company
5.	Address of the Registered office & contact details	Prop No. 1704, PVT SHOP NO. 1, F/F BHAGIRATH PALACE, CHANDNI CHOWK, DELHI-110006
6.	Whether listed company	NO
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	N.A.

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	Pharmaceutical products	99612730	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

Sr. No.	Name and address of the Company	CIN/GLN/Registration No.	Holding/ Subsidiary /Associate	% of Shares held
1.	IBERIA SKIN BRANDS LIMITED (UK)	11213638	Subsidiary	100

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-Wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year	No. of Shares held at the end of the year	%Change during the year

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
(1) Indian									
Individual/ HUF	-	103750	103750	-	-	103750	103750	-	100%
Central Government	-	-	-	-	-	-	-	-	-
State Government	-	-	-	-	-	-	-	-	-
Bodies Corporate	-	-	-	-	-	-	-	-	-
Banks / FI	-	-	-	-	-	-	-	-	-
Any other	-	-	-	-	-	-	-	-	-
Sub Total (A)(1)	-	103750	103750	-	-	103750	103750	-	100%
(2) Foreign	-	-	-	-	-	-	-	-	-
NRI	-	-	-	-	-	-	-	-	-
Other Individual	-	-	-	-	-	-	-	-	-
Bodies Corporate	-	-	-	-	-	-	-	-	-
Banks	-	-	-	-	-	-	-	-	-
Any other	-	-	-	-	-	-	-	-	-
Sub Total (A) (2)	-	-	-	-	-	-	-	-	-
Total shareholding	-	103750	103750	-	-	103750	103750	-	100%

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

for GDRs & ADRs									
GRAND TOTAL (A+B+C)	-	93750	-	-	-	-	93750	-	90.36%

ii) Shareholding of Promoters:

S. No.	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			
		No. of Shares	% of total Shares of the Co.	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Co.	% of Shares Pledged / encumbered to total shares	
1.	PRAVEEN JAIN	2400	2.31%	2.31%	0	0.00%	0.00%	N.A.
2.	RISHAB JAIN	2400	2.31%	2.31%	2400	2.31%	2.31%	N.A.
3.	NITIN JAIN	5200	5.02%	5.02%	7600	7.33%	7.33%	N.A.

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

iii) Change in Promoters' Shareholding: -N.A.

Sr. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the Co.	No. of shares	% of total shares of the company
	At the beginning of the year	-	-	-	-
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat Equity etc.)	-	-	-	-
	At the End of the Year.	-	-	-	-

iv) Shareholding Pattern of top Ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs: - N.A.

Sr. No.	Name of the Shareholder	Shareholding at the beginning of the Year		Cumulative Shareholding during the Year	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
	SHIVANI JAIN				
	For Each of the Top 10 Shareholders				
	At the beginning of the year	93750	90.36%	93750	90.36%
	Date wise Increase / Decrease in Shareholding during the Year specifying the reasons for increase / decrease (e.g. allotment/transfer/bonus/Sweat Equity etc.)	-	-	-	-
	At the End of the year (or on the date of separation, if separated during the year)	-	-	-	-

v) Shareholding of Directors and Key Managerial Personnel:-

Sr. No.		Shareholding at the beginning of the year	Cumulative Shareholding during the year
---------	--	---	---

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

	For Each of the Directors and KMP	No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
1.	PRAVEEN JAIN				
	At the beginning of the year	2400	2.31	0	0.00
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc)	-	-	-	-
	At the End of the year	2400	2.31	0	0.00
2.	RISHAB JAIN				
	At the beginning of the year	2400	2.31	2400	2.31
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc)	-	-	-	-
	At the End of the year	2400	2.31	2400	2.31
3.	NITIN JAIN				
	At the beginning of the year	5200	5.02	5200	5.02
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc)	-	-	-	-
	At the End of the year	5200	5.02	7600	7.33
4.	SHIVANI JAIN				
	At the beginning of the year	93750	90.36	93750	90.36
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc)	-	-	-	-
	At the End of the year	93750	90.36	93750	90.36

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

V. INDEBTEDNESS

Indebtedness of the Company including Interest outstanding/accrued but not due for Payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i. Principal Amount	6,40,838.00	-	NIL	6,40,838.00
ii. Int. due but not paid				
iii. Interest accrued but not due				
Total (i + ii + iii)	6,40,838.00	-	NIL	6,40,838.00
Change in Indebtedness during the Financial Year				
. Addition			NIL	
. Reduction	(2,51,065.00)	-		(2,51,065.00)
Net Change	(2,51,065.00)	-	NIL	(2,51,065.00)
Indebtedness at the end of the financial year				
i. Principal Amount	3,89,773.00	-	NIL	3,89,773.00
ii. Int. due but not paid				
iii. Interest accrued but not due				
Total (i + ii + iii)	3,89,773.00	-	NIL	3,89,773.00

V. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

(A). Remuneration to Managing Director, Whole-time Directors and/or Manager:-

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager*			Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-			-
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission – as % of profit - other, specify	-	-	-	-

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

5.	Other, please specify	-	-	-	-
	Total (A)	-			-
	Ceiling as per the Act	N.A on Private Limited Companies			

* Remuneration paid to Executive Directors as there is No MD and WTD in the Company

B. Remuneration to other Directors:-

Sr. No.	Particulars of Remuneration	Name of Director		Total Amount
1.	1. Independent Directors			
	• Fee for attending Board Committee Meetings • Commission • Others, please specify	-	-	-
	Total (1)	-	-	-
2.	2. Other Non-Executive Directors			
	• Fee for attending Board Committee Meetings • Commission • Others, please specify [Remuneration]	-	-	-
	Total (2)			
	Total (B)=(1+2)			
	Overall Ceiling as per the Act	N.A.	N.A.	N.A.

C. Remuneration to key managerial personnel other than MD/Manager/WTD:-

Details are as follows:-

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961				
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	
	(c) Profits in lieu of salary under Section 17(3) Income-tax Act, 1961	-	-	-	
2.	Stock Option	-	-	-	-

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

1704 PVT SHOP NO. 1 F/F BHAGIRATHI PALACE CHANDANI CHOWK DELHI-110006

CIN No. U24232DL2013PTC250040

3.	Sweat Equity	-	-	-	-
4.	Commission – as % of profit - other, specify	-	-	-	-
5.	Other, Variable pay	-	-	-	-
	Total				

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES: -

Type	Section of the Companies Act, 1956	Brief Description	Details of penalty / punishment/Compounding fees imposed	Authority (RD/NCLT Court/CLB)	Appeal made, if any (give details)
A. COMPANY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
B. MANAGING DIRECTOR					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
C. DIRECTOR					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
D. COMPANY SECRETARY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-

FOR AND ON BEHALF OF
SATNAM MEDICAL AGENCIES PRIVATE LIMITED



Nitin Jain
Director
DIN: 05276862

August 9th, 2022
New Delhi

FORM NO. AOC.2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso Thereto

1. Details of contracts or arrangements or transactions not at arm's length basis

- (a) Name(s) of the related party and nature of relationship
- (b) Nature of contracts/arrangements/transactions
- (c) Duration of the contracts/arrangements/transactions
- (d) Salient terms of the contracts or arrangements or transactions including the value, if Any
- (e) Justification for entering into such contracts or arrangements or transactions
- (f) Date of approval by the Board
- (g) Amount paid as advances, if any:
- (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188

2. Details of material contracts or arrangement or transactions at arm's length basis

- (a) Name(s) of the related party and nature of relationship
NIL
 - (b) Nature of contracts/arrangements/transactions
 - (c) Duration of the contracts/arrangements/transactions
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any:
 - (e) Date(s) of approval by the Board, if any:
 - (f) Amount paid as advances, if any:
- Form shall be signed by the persons who have signed the Board's report.

**FOR AND ON BEHALF OF
SATNAM MEDICAL AGENCIES PRIVATE LIMITED**


Nitin Jain
Director
DIN: 05276862
August 9th 2022

ARUN PRAKASH PANJRATH & ASSOCIATES

CHARTERED ACCOUNTANTS

ADD: - K-1/139, FIRST FLOOR, CHITTRANJAN PARK, NEW DELHI- 110019

TELEPHONE: - 011-42567105

EMAIL: - FCA@PANJRATH.COM, PANJRATH@PANJRATH.COM

Independent Auditors' Report

To The Members of **Satnam Medical Agencies Private Limited**,
1704, PVT Shop No-1, F/F Bhagirathi Palace Chandni Chowk,
New Delhi-110006

Report on the standalone Financial Statements

We have audited the accompanying standalone financial statements of **Satnam Medical Agencies Private Limited** ("the Company") which comprises the Balance Sheet as at **March 31, 2022**, the Statement of Profit and Loss for the year then ended and a summary of significant accounting policies and other explanatory information.

Management's responsibility for the Financial Statements

1. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and Accounting Standard 30. Financial Instruments: Recognition and managements issued by the institute of chartered accountants of India to the extent it does not contradict any other accounting standard refer to in Section 133 of The Act read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

2. Our responsibility is to express an opinion on these standalone financial statements based on our audit.
3. We have taken into account the provisions of the Act and the rules made there under include the accounting standards, the accounting and auditing standards and matters which are required to be included in the audit report.
4. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncement issued by the Institute of

Chartered Accountants of India. Those Standards and pronouncements require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

5. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.
6. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

7. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **31st March, 2022**, and its profit for the year ended on that date.

Report on Other Legal and Regulatory requirements

8. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Companies Act, 2013(hereinafter referred to as the "Order"), and on the basis of such checks of books and records of the Company as we considered appropriate and according to the information and explanation given to us, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order.
9. As required by section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and Accounting Standard 30, financial instruments: Recognitions and Measurement issued by the Institute of Chartered Accountants of India to the extent it does not contradict any other accounting standard referred to in Section 133 of the Act read with Rule 7 of Companies (Accounts) Rules 2014,

- e) On the basis of the written representations received from the directors as on **March 31, 2022** taken on record by the Board of Directors, none of the directors is disqualified as on **31st March, 2022** from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With Respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in **Annexure B**.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our knowledge and belief and according to the information and explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses ;
 - iii. There is no requirement of transferring amounts to the Investor Education and Protection Fund by the Company, as the rules are not applicable to the company.

For Arun Prakash Panj Rath And Associates
Chartered Accountants
F.R.N: 006963N

Aruneesh Panj Rath



Aruneesh Panj Rath
Partner
(Membership No. 559636)
August 9th, 2022
New Delhi

Annexure A To Independent Auditors' Report

Referred to in paragraph (9) of Independent Auditors' Report under the heading of "Report on Other Legal and Regulatory requirements" of our report of even date

(i)	(a)	The company has maintained proper records showing full particulars including quantitative details and situation, of fixed assets.		
	(b)	All the fixed assets of the Company have been physically verified by the Management according to a regular program, which, in our opinion, is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies with respect to book records were noticed on such verification.		
	(c)	All the title deeds of immovable properties are held in the name of the company.		
	(d)	The Company has not revalued its property, plant and equipment (including right of use of assets) or intangible asset of both during the financial year;		
	(e)	No proceeding have been initiated or pending against company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.		
		Depreciation has been provided on SLM basis on various Fixed Assets as per company policies method of charging Depreciation as well as groupings have been rearranged, regrouped as per company policies.		
(ii)	(a)	Physical verification of inventory (except material in transit) has been conducted by the management at reasonable intervals. In our opinion, the frequency of verification is reasonable.		
	(b)	During any point of time of the year, the company has not been sanctioned any working capital limits, from banks or financial institutions on the basis of security of current assets. Therefore, the provisions of Clause (ii) (b) of paragraph 3 of the order are not applicable to the company.		
(iii)		According to the information and explanations given to us, the Company has not granted any loan to companies, firms or other parties covered in the Register maintained under section 189 of the Act and as such clauses (iii) (a) and (b) of the order are not applicable to the company.		
		Particulars	2021-22	2020-21
		N.A.	N.A.	N.A.
(iv)		The Company has not granted any loans or made any investments, or provided any guarantees or security to the parties covered under Section 185 and 186. Therefore, the provisions of Clause 3(iv) of the said Order are not applicable to the Company.		
(v)		According to the information and explanation given to us, the Company has not accepted any deposit from the public within the meaning of Section 73, 74, 75 and 76 of the Act and the Rules framed there under to the extent notified.		
(vi)		Pursuant to the rules made by the Central Government of India, the Company is not required to Maintained Cost Records as specified under Section 148(1) of the Act in		

	respect of its products.
(vii) (a)	According to the information and explanation given to us, and the records of the Company examined by us, in our opinion, The company is generally regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees state insurance, income tax, sales tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues applicable to it. According to the information and explanations given to us, no undisputed amounts payable in respect thereof were outstanding as at 31st March,2022 for a period of more than six months from the date they became payable.
(b)	According to the information and explanation given to us, and the records of the Company examined by us, there are no dues of income-tax or sales tax or wealth-tax or service tax or duty of customs or duty of excise or value added tax or cess which have not been deposited on account of any dispute.
(viii)	According to the records of the Company examined by us and the information and explanation given to us, the Company has not defaulted in repayment of loans or borrowings to any financial institution or bank or Government or dues to debenture holders as at the balance sheet date.
(ix)	(a) The Company has raised moneys by way of car loan of which outstanding amount is of Rs. 3,89,773. (b) The company has not been declared willful defaulter by any bank or financial institution or other lender, hence this clause is not applicable; (c) The company has not obtained any term loans. (d) The company has not raised any short term funds in the form of Overdraft limits. (e) The company has not taken any any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures; hence this clause is not applicable; (f) The company has not raised company has raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies; hence this clause is not applicable.
(x) (a)	The Company did not raise any money by way of initial public offer or further public offer (including debt instruments); hence this clause is not applicable;
(b)	The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year; hence this clause is not applicable
(xi) (a)	According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
(b)	No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government; hence this clause is not applicable
(xii) (a)	The Company is not a Nidhi Company hence compliance of Net Owned Funds to Deposits in the ratio of 1: 20 to meet out the liability is not applicable to the company;

(b)	The Company is not a Nidhi Company hence maintaining ten percent unencumbered term deposits as specified in the Nidhi Rules, 2014 to meet out the liability is not applicable to the company;
(c)	The Company is not a Nidhi Company hence this clause is not applicable to the company.
(xiii)	According to the information and explanation given to us and based on the our examination of the records of the company, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable and the details have been disclosed in the financial statements, etc., as required by the applicable accounting standards.
(xiv) (a)	The Central Government has not prescribed to appoint internal auditor under section 138 of the Act, for any of the services rendered by the Company;
(b)	This clause is not applicable to the company.
(xv)	According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him as restricted in section 192 of Companies Act, 2013; hence this clause is not applicable.
(xvi) (a)	The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.
(b)	The Company is not has conducted any Non-Banking Financial or Housing Finance activities; hence this clause is not applicable.
(c)	The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India; hence this clause is not applicable.
(d)	The Company does not have any CIC.
(xvii)	The company has not incurred cash losses in the financial year and in the immediately.
(xviii)	No dividend has been declared or paid during the year by the company and is in compliance with section 123 of the Companies Act, 2013
(xix)	According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not assurance that all liabilities falling due within a period of one year from the balance sheet due date, will get discharged by the company as and when they fall due.
(xx) (a)	The company has not any other than ongoing projects, therefore provision of section 135 of Companies Act, 2013 is not applicable to the company;
(b)	This clause is not applicable to the company.
(xxi)	(a) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that

	the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
(b)	The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
(c)	Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement
(xxii)	There are no any qualifications or adverse remarks given by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports, hence this clause is not applicable to the company.

For Arun Prakash Panjraht And Associates
Chartered Accountants
F.R.N: 006963N

Arun Prakash Panjraht



Arun Prakash Panjraht
Partner
(Membership No. 559636)
August 9th, 2022
New Delhi

Annexure B to Independent Auditors' Report

Referred to in paragraph 10(f) of the independent Auditors' Report under the heading of "Report on Other Legal and Regulatory requirements" of our report of even date

Report on internal Financial Controls under Clause (i) of Sub-section 3 of section 143 of the Act.

1. We have audited the internal financial controls over financial reporting of **Satnam Medical Agencies Private Limited** ("the Company") as of **March 31, 2022** in conjunction with our audit of the standalone financial statement of the Company for the ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under Section 143(10) of the Act the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respect.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial statement, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning Of Internal Financial Controls Over Financial Reporting

6. A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purpose in accordance with generally accepted accounting principles. A company's internal financial control over financial over financial reporting

includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitation of Internal Financial Controls Over Financial Reporting

7. Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at **March 31, 2022**, based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Arun Prakash Panj Rath And Associates
Chartered Accountants
F.R.N: 006963N

Aruneesh Panj Rath



Aruneesh Panj Rath
Partner
(Membership No. 559636)
August 9th, 2022
New Delhi

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31 MARCH, 2022

(Rs in Lakhs)

	Particulars	Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
			Amount (Rs.)	Amount (Rs.)
A	CONTINUING OPERATIONS			
1	Revenue from operations (gross)	15	4,370.76	153.65
2	Other income	15.a	9.32	0.48
3	Total Income (1+2)		4,380.08	154.14
4	Expenses			
	(a) Cost of materials consumed	16.a	-	-
	(b) Purchases of stock-in-trade	16.b	4,234.67	104.26
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.c	-	-
	(d) Employee benefits expense	17	37.31	30.72
	(e) Finance costs	18	0.60	0.65
	(f) Depreciation and amortisation expense	9	5.11	4.94
	(g) Other expenses	19	50.83	10.70
	Total expenses		4,328.52	151.27
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		51.56	2.86
6	Exceptional items		-	-
7	Profit / (Loss) after extraordinary items and tax (5 ± 6)		51.56	2.86
8	Extraordinary items		-	-
9	Profit / (Loss) before tax (7 ± 8)		51.56	2.86
10	Tax expense:			
	(a) Current tax expense for current year		13.31	0.90
	(b) (Less): MAT credit (where applicable)		-	-
	(c) Current tax expense relating to prior years		-	-
	(d) Net current tax expense		13.31	0.90
	(e) Deferred tax		(0.31)	(0.15)
			13.00	0.74
11	Profit / (Loss) from continuing operations (9 ± 10)		38.56	2.12
B	DISCONTINUING OPERATIONS			
12.i	Profit / (Loss) from discontinuing operations (before tax)		-	-
12.ii	Gain / (Loss) on disposal of assets / settlement of liabilities attributable to the discontinuing operations		-	-
12.iii	Add / (Less): Tax expense of discontinuing operations		-	-
	(a) on ordinary activities attributable to the discontinuing operations		-	-
	(b) on gain / (loss) on disposal of assets / settlement of liabilities		-	-
13	Profit / (Loss) from discontinuing operations (12.i ± 12.ii ± 12.iii)		-	-
C	TOTAL OPERATIONS			
14	Profit / (Loss) for the year (11 ± 13)		38.56	2.12



Amresh Panjrat



[Signature]

[Signature]

Statement of Profit and Loss for the year ended 31 March, 2019 (contd.)

Particulars		Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
			Amount (Rs.)	Amount (Rs.)
15.i	Earnings per share (of ` Rs. 10/- each):			
	(a) Basic			
	(i) Continuing operations	20.a	385.56	21.19
	(ii) Total operations	20.b	385.56	21.19
	(b) Diluted			
	(i) Continuing operations	20.e	385.56	21.19
	(ii) Total operations	20.f	385.56	21.19
15.ii	Earnings per share (excluding extraordinary items) (of ` Rs. 10/- each):			
	(a) Basic			
	(i) Continuing operations	20.c	385.56	21.19
	(ii) Total operations	20.d	385.56	21.19
	(b) Diluted			
	(i) Continuing operations	20.g	385.56	21.19
	(ii) Total operations	20.h	385.56	21.19
Notes to Accounts forming integral part of Financial Statements				
IN TERMS OF OUR SEPARATE AUDIT REPORT OF EVEN DATE ATTACHED				
For ARUN PRAKASH PANJRATH & ASSOCIATES			For and on behalf of the Board of Directors of	
Chartered Accountants			SATNAM MEDICAL AGENCIES PRIVATE LIMITED	
FRN:006963N				
				
(A.C.A. ARUNEESH PANJRATH)			Director	
Partener			RISHABH JAIN	
M. NO. 559636				
Place : NEW DELHI			Director	
Date : 09/08/2022			NITIN JAIN	
UDIN:- 22559636AYVRQY8853			5276845	
			05276862	

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
1704 PVT SHOP NO. 1 FF BHAGIRATH PALACE CHANDANI CHOWK DELHI
BALANCE SHEET AS AT 31st MARCH 2022

(Rs in Lakhs)

Particulars	Note No.	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	10.38	10.38
(b) Reserves and surplus	2	130.77	92.21
(c) Money received against share warrants		-	-
		141.14	102.59
2 Share application money pending allotment		60.45	60.45
3 Non-current liabilities			
(a) Long-term borrowings	3	-	-
(b) Deferred tax liabilities (net)	21	-	-
(c) Other long-term liabilities		-	-
(d) Long-term provisions	4	-	-
4 Current liabilities			
(a) Short-term borrowings	5	3.90	6.41
(b) Trade payables	6	1,985.00	1,223.78
(c) Other current liabilities	7	25.42	1.82
(d) Short-term provisions	8	13.31	0.90
		2,027.63	1,232.90
TOTAL		2,229.22	1,395.94
B ASSETS			
1 Non-current assets			
(a) Property, plant and equipment and Intangible assets			
(i) Property, plant and equipment	9	205.28	207.82
(ii) Intangible assets	9	-	-
(iii) Capital work-in-progress	9	-	-
(iv) Intangible assets under development	9	-	-
(v) Fixed assets held for sale		-	-
		205.28	207.82
(b) Non-current investments	9.a.i	387.57	317.72
(c) Deferred tax assets (net)	21	1.08	0.77
(d) Long-term loans and advances	10	15.67	52.52
(e) Other non-current assets	10.a	-	-
		404.32	371.01
2 Current assets			
(a) Current investments	9.a.ii	464.55	-
(b) Inventories	11	350.45	170.38
(c) Trade receivables	12	715.28	628.77
(d) Cash and cash equivalents	13	72.64	16.78
(e) Short-term loans and advances	14	16.70	1.18
(f) Other current assets		-	-
		1,619.62	817.11
TOTAL		2,229.22	1,395.94
Notes to Accounts forming integral part of Financial Statements	22	-	-

IN TERMS OF OUR SEPARATE AUDIT REPORT OF EVEN DATE ATTACHED

For ARUN PRAKASH PANJRATH & ASSOCIATES

Chartered Accountants

FRN:006963N

Arun Prakash Panjrath
(A.C.A. ARUNEESH PANJRATH)

Partner
M. NO 559636

Place : New Delhi

Date 09/08/2022

UDIN:- 22559636AYVRQY8853

For and on behalf of the Board of Directors

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Rishabh Jain
Director
RISHABH JAIN
5276845

Nitin Jain
Director
NITIN JAIN
05276862

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

(Rs in Lakhs)

Particulars	For the Year ended March 31, 2022	For the year ended March 31, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	51.56	2.86
Adjustments for:		
Depreciation and amortisation expense	5.11	4.94
(Profit) / Loss on sale of fixed assets		
(Profit) / Loss on redemption of investments		
Interest and other income on investments	(9.32)	(0.48)
Interest expenses		
Tax Expense	(13.00)	(0.74)
Operating profit / (loss) before working capital changes	34.34	6.57
Changes in working capital:		
Increase / (Decrease) in trade payable	761.22	(15.30)
Increase / (Decrease) in short term borrowing	(2.51)	(5.02)
Increase / (Decrease) in provisions	12.41	(0.60)
Increase / (Decrease) in deferred tax liabilities	-	
(Increase) / Decrease in deferred tax Assets	(0.31)	(0.15)
Increase / (Decrease) in other current liabilities	23.60	(0.26)
(Increase) / Decrease in short term loan and advances	(15.52)	6.06
(Increase) / Decrease in trade receivables	(86.51)	88.60
(Increase) / Decrease in inventories	(180.06)	10.14
(Increase) / Decrease in other current assets		90.08
	512.31	173.54
CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	546.66	180.11
Less: Taxes paid		
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	546.66	180.11
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible / intangible assets	(2.57)	(187.38)
Sale of tangible / intangible assets		
(Increase) / Decrease in long term loan and advances	36.85	(1.50)
(Increase) / Decrease in Non-Current Investments	(69.85)	
Investment in fixed deposits	(464.55)	
Dividend/ bank interest received	-	-
NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES	(500.12)	(188.88)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest Income	9.32	0.48
Increase/(Decrease) in Long-Term Borrowing	-	
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	9.32	0.48
NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	55.86	(8.28)
Cash and Cash equivalents at beginning period (Refer Note 14)	16.78	25.07
Cash and Cash equivalents at end of period (Refer Note 14)	72.64	16.78
D. Cash and Cash equivalents comprise of		
Cash on hand	2.63	1.43
Balances with banks		
In current accounts	70.01	15.36
Total	72.64	16.78
	(0)	0

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"

Significant accounting policies

Notes referred to above form an integral part of the Financial Statements.

As per our report of even date
For *Arjun Prakash Panjra & Associates*
Chartered Accountants
ICAI F.R.No. 006963N

Arjun Panjra
M.No.: 559636
Date:- 9/8/22
Place:- New Delhi



For & On Behalf of the Board

Arjun Panjra
Director
RISHABH JAIN

5276845

Arjun Panjra
Director
NITIN JAIN

05276862

Notes forming part of the financial statements

Note 1 Share capital

(Rs in Lakhs)

	Particulars	As at 31 March, 2022		As at 31 March, 2021	
		Number of shares	Amount	Number of shares	Amount
(a) Authorised	Equity shares of Rs.10 each with voting rights	10	101.00	10	101.00
(b) Issued	Equity shares of Rs.10 each with voting rights	1	10.38	1	10.38
(c) Subscribed and fully paid up	Equity shares of Rs.10 each with voting rights	1	10.38	1	10.38
	Total	1	10.38	1	10.38
i	The Company has only Equity Share capital. The Equity Shares has been further bifurcated in to Authorised, Issued, Subscribed and Paid Equity capital.				

Particulars					
Notes:					
(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period: 31.03.2022					
Details of Equity Shares separately for Issued, Subscribed and fully paid up and Subscribed but not fully paid up, as applicable.					
Particulars	Opening Balance	Fresh issue	Bonus	others i.e. Esop/Conversion/Buy Back	Closing Balance
Equity shares with voting rights					
Year ended 31 March, 2018					
- Number of shares	0	-	-	-	0
- Amount (Rs. 10/- per share)	1	-	-	-	0
Year ended 31 March, 2019					
- Number of shares	0	0.94	-	-	1
- Amount (Rs. 10/- per share)	1	9.38	-	-	10

Shares held by promoters at the end of the year 31st March 2022				
Sr. No.	Promoter Name	No. of Shares**	% of total shares**	Change during the year
1	SHIVANI JAIN	0.9375	90.36%	90.36%
2	PRAVEEN JAIN	0	0%	2.31%
3	NITIN JAIN	0.076	7%	5.01%
4	RISHAB JAIN	0.024	2.31%	2.31%
	Total	1	7%	

Shares held by promoters at the end of the year ending 31st March 2021				
Sr. No.	Promoter Name	No. of Shares**	% of total shares**	Change during the year
1	SHIVANI JAIN	0.9375	90.36%	90.36%
2	PRAVEEN JAIN	0	0%	2.31%
3	NITIN JAIN	0.076	7%	5.01%
4	RISHAB JAIN	0.024	2.31%	2.31%
	Total	1	7%	



Anurag Jain

[Signature]

Note 2 Reserves and surplus

		(Rs in Lakhs)	
Particulars		As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
(c) Securities premium account			
Opening balance		65.63	65.63
Add : Premium on shares issued during the year		-	-
Less : Utilised during the year		-	-
Closing balance		65.63	65.63
(i) Surplus / (Deficit) in Statement of Profit and Loss			
Opening balance		26.59	24.47
Add: Profit / (Loss) for the year		38.56	2.12
Closing balance		65.14	26.59
Add: adjustment reserve & surplus diff		-	-
I tax for Ass Yr 2019-20		-	-
Less: provision for income tax ass year		-	-
Total		130.77	92.21

Sumesh Panjra



Ashwani

Sr

Note 3 Long-term borrowings

		(Rs in Lakhs)	
	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Term loans		
	From banks		
	Secured (Bank)	-	-
	Unsecured	-	-
	From other parties		
	Secured	-	-
	Unsecured	-	-
	(b) Loans and advances from related parties		
	Secured	-	-
	Unsecured	-	-
	Total	-	-

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 3 Long-term borrowings (contd.)

Particulars					
Details of terms of repayment for the other long-term borrowings and security provided in respect of the secured other long-term borrowings:					
Particulars	Terms of repayment and security	As at 31 March, 2022		As at 31 March, 2021	
		Secured	Unsecured	Secured	Unsecured
		Amount (Rs.)	Amount (Rs.)	Amount (Rs.)	Amount (Rs.)
Term loans from banks:					
		-	-	-	-
Total - Term loans from banks		-	-	-	-
Loans and advances from related parties:					
From Director-		-	-	-	-
		-	-	-	-
		-	-	-	-
		-	-	-	-
Total - Loans and advances from related parties		-	-	-	-

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 5. Short-term borrowings

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Loans repayable on		
	From banks		
	Secured	3.90	6.41
	Unsecured	-	-
	From other parties		
	Secured	-	-
	Unsecured	-	-
	Total	3.90	6.41

Notes:

(i) Details of security for the secured short-term borrowings:

	Particulars	Nature of security	As at 31 March, 2022	As at 31 March, 2021
			Amount (Rs.)	Amount (Rs.)
	Loans repayable on demand from banks:			
	DCB Bank		3.90	6.41
	Total - from banks		3.90	6.41
	Loans and advances from related parties:			
			-	-
	Total - Loans and advances from related parties		-	-

Ashish Gaur

Ja

Ashish Gaur



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 4 Long-term provisions

Particulars	(Rs in Lakhs)	
	As at 31 March, 2021	As at 31 March, 2020
	Amount (Rs.)	Amount (Rs.)
(a) Provision for employee benefits:		
(i) Provision for compensated absences	-	-
(ii) Provision for gratuity (net)	-	-
(iii) Provision for post-employment medical benefits	-	-
(iv) Provision for other defined benefit plans (net) (give detail)	-	-
(v) Provision for other employee benefits (give details)	-	-
(b) Provision - Others:		
(i) Provision for premium payable on redemption of bonds	-	-
(ii) Provision for estimated loss on derivatives	-	-
(iii) Provision for warranty (Refer Note 30.14)	-	-
(iv) Provision for estimated losses on onerous contracts	-	-
(v) Provision for other contingencies	-	-
(vi) Provision - others	-	-
Total	-	-

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 8. Short-term provisions

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
	Amount (Rs.)	Amount (Rs.)
(a) Provision for employee benefits:		
(i) Provision for bonus	-	-
(ii) Provision for Leave in cashment	-	-
(iii) Provision for gratuity (net) (Refer Note 30.4.b)	-	-
(b) Provision - Others:		
(i) Provision for tax (A/Y 2022-23)	13.31	-
(ii) Provision for tax (A/Y 2021-22)	-	0.90
(ii) Provision for tax (A/Y 2020-21)	-	-
	13.31	0.90
Total	13.31	0.90

Aruneesh Jain



Aruneesh Jain

Aruneesh Jain

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements
Note 6. Trade payables

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Trade payables:		
Trade payables:	1,985.00	1,223.78
Other payables	-	-
Total	1,985.00	1,223.78

TRADE PAYABLES :	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Sundry Creditors	1,985.00	1,223.78
Total (Rs.)	1,985.00	1,223.78

Trade Payables ageing
schedule: As at 31st
March, 2022

(Rs in Lakhs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	3 year	More than 3 years	
(i) MSME	1,985.00				1,985.00
(ii) Others					-
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-

Trade Payables ageing
schedule: As at 31st March
2021

(Rs. in Thousand)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	3 year	More than 3 years	
(i) MSME	1,223.78				1,223.78
(ii) Others					-
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-

Aswameesh Jain
Chartered Accountants
New Delhi

Aswameesh Jain
JS

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 7. Other current liabilities

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
(j) Other payables	-	-
(i) Statutory remittances	21.22	1.82
(viii) Others (Expenses Payable)	4.20	-
Total	25.42	1.82

Statutory Remittance

As at 31 March, 2022

As at 31 March, 2021

	<u>Amount (Rs.)</u>	<u>Amount (Rs.)</u>
Gst Payable	19.20	-
TDS Payable	2.01	0.01
Salary Payable	-	1.81
	<u>21.22</u>	<u>1.82</u>

Expenses Payable

As at 31 March, 2022

As at 31 March, 2021

	<u>Amount (Rs.)</u>	<u>Amount (Rs.)</u>
Interest Payable	-	-
Rent Payable	4.20	-
Expenses Payable	-	-
Professional Charges Payable	-	-
Total (Rs.)	<u>4.20</u>	<u>-</u>

Arun Prakash Jain
Chartered Accountants
New Delhi

Ashok Kumar
JS

Notes forming part of the financial statements

Note 9. Fixed assets

(Rs in Lakhs)

	Fixed Assets	PERIO D	Rate of Dep.	Gross Block					Accumulated Depreciation					Net Block	
				Balance as at 1st April 2021	Additions	(Disposals)	Acquired through business combination	Revaluations/ (Impairments)	Balance as at 31st March 2022	Balance as at 1st April 2021	Depreciation charge for the year	Adjustment due to revaluations	On disposals	Balance as at 31st March 2022	Balance as at 31st March 2021
a	Tangible Assets														
	Car	8	11.88%	30.93	-	-	-	30.93	16.90	3.67	-	-	20.57	14.03	10.36
	Airconditioner	10	9.50%	1.32	-	-	-	1.32	0.52	0.13	-	-	0.64	0.80	0.68
	Computer	6	15.83%	3.51	-	-	-	3.51	2.20	0.56	-	-	2.75	1.31	0.75
	Printer	6	15.83%	0.10	-	-	-	0.10	0.05	0.02	-	-	0.07	0.04	0.03
	Mobile Phone	8	11.88%	2.56	-	-	-	2.56	0.58	0.30	-	-	0.89	1.98	1.68
	Furniture & Fittings	10	9.50%	2.76	2.57	-	-	5.34	0.49	0.44	-	-	0.92	2.28	4.41
	Land		0.00%	187.38	-	-	-	187.38	-	-	-	-	-	187.38	187.38
				-	-	-	-	-	-	-	-	-	-	-	-
	Total			228.56	2.57	-	-	231.13	20.74	5.11	-	-	25.85	207.82	205.28
b	Intangible Assets														
	Goodwill			-	-	-	-	-	-	-	-	-	-	-	-
	Brands / trademarks			-	-	-	-	-	-	-	-	-	-	-	-
	Computer software		25.89%	-	-	-	-	-	-	-	-	-	-	-	-
	Mastheads and publishing titles			-	-	-	-	-	-	-	-	-	-	-	-
	Mining rights			-	-	-	-	-	-	-	-	-	-	-	-
	Copyrights, and patents and other intellectual property rights, services and operating rights			-	-	-	-	-	-	-	-	-	-	-	-
	Recipes, formulae, models, designs and prototypes			-	-	-	-	-	-	-	-	-	-	-	-
	Licenses and franchise			-	-	-	-	-	-	-	-	-	-	-	-
	Others (specify nature)			-	-	-	-	-	-	-	-	-	-	-	-
	Total			-	-	-	-	-	-	-	-	-	-	-	-
c	Capital Work In Progress														
	Total			-	-	-	-	-	-	-	-	-	-	-	-
d	Intangible assets under Development														
	Total			228.56	-	-	-	231.13	20.74	5.11	-	-	25.85	207.82	205.28

Note 2:- Disclosure pursuant to Note no.I (iv) and J (iii) of Part I of Schedule VI to the Companies Act, 1956

Details of amounts written off on reduction of capital or revaluation of assets or sums added to assets on revaluation during the preceding 5 years:

Particulars			Year				
			2019-20	2018-19	2017-18	2016-17	2015-16
Asset details:							
Balance as at 1 April							
Impairment/ Revaluation							
Balance as at 31 March							

Asset	Rate	Buying Date	End of Year	Days	Value	Dep.
1 Furniture	9.50%	28/04/2021	31/03/2022	338	1.392125	0.12246886
2 Furniture	9.50%	13/10/2021	31/03/2022	170	1.1814	0.052272904
Total				508	2.573525	0.174741764



Ashwini Panjra
Chartered Accountants
New Delhi

Additional Regulatory Information

CARO 3(I)(c)

i) Title deeds of Immovable Property not held in name of the Company

(Rs. in Lakhs)

Relevant line item in Balance Sheet	Description of item of property	Gross Carrying Value	Title deeds held in the name of	Whether the deeds held in the name of promoter, director or relative of promoter/director or employee of promoter/director	Property held since which date	Reasons for not being held in the name of the company*
PPE						
Investment property						
disposal						
Others						

*also indicate if in dispute

Capital-Work-in Progress (CWIP) / Intangible assets under development (ITAUD)

(Amount in Rs.)

CWIP/ITAUD	Amount in CWIP for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

iv) Capital-Work-in Progress (CWIP)/ITAUD whose completion (Amount in Rs.)

CWIP/ITAUD	To be completed in			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
Project 1	-	-	-	-
Project 2	-	-	-	-

Asameesh Jain



Deshegiri

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 9.a Investments

(i) Non-Current Investments		(Rs in Lakhs)	
	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Investments in Iberia SkinBrands Ltd. (UK)	316.86	246.68
	Investments in Iberia SkinBrands India Pvt. Ltd. (India)	9.00	9.00
	PHEASANTZ PHARMA SOLUTIONS PRIVATE LIMITED	61.71	62.04
	Total	387.57	317.72

(ii) Current Investments			
	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Sweep A/c	464.55	-
	Total	464.55	-

Aswameesh Jain



Aswameesh Jain

[Signature]

SCHEDULE OF FIXED ASSETS

(Rs in Lakhs)

PARTICULARS	Rate of Dep.	W.D.V. as on	Addition during the year		As. On 31.03.2022	Dep. Charges dur. The year	Net Block 31.03.2022
		01.04.2021	before 180 days	after 180 days			
Furniture & Fitting	10%	2.25	1.39	1.18	4.83	0.42	4.40
Car	15%	17.80	-	-	17.80	2.67	15.13
Airconditioner	15%	0.74	-	-	0.74	0.11	0.63
Computer	40%	0.76	-	-	0.76	0.30	0.45
Mobile Phone	15%	1.81	-	-	1.81	0.27	1.54
Printer	15%	0.06	-	-	0.06	0.01	0.05
Land		187.38	-	-	187.38	-	187.38
		210.79	1.39	1.18	213.36	3.79	209.58



Ashu Prakash

Chaudhary

Note 10 Long-term loans and advances

		(Rs in Lakhs)	
Particulars	As at 31 March, 2022	As at 31 March, 2021	
	Amount (Rs.)	Amount (Rs.)	
(i) Security Deposit			
Secured, considered good	3.65		5.00
Unsecured, considered good	10.02		17.52
Doubtful	-		-
	13.67		22.52
Less: Provision for doubtful deposits	-		-
	13.67		22.52
(b) Advance income tax (net of provisions) - Unsecured, considered good			
For the A/Y- 2016-17	-		-
For the A/Y- 2022-23	2.00		-
(c) Other loans and advances (specify nature)			
Secured, considered good			
Unsecured, considered good	-		30.00
Doubtful	-		-
	-		30.00
Less: Provision for other doubtful loans and advances	-		-
	-		30.00
Total	15.67		52.52

Following disclosures shall be made where Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are:

- (a) repayable on demand or
- (b) without specifying any terms or period of repayment

Type of Borrower	nature of loan outstanding	the total Loan
Promoters		
Directors		
KMPs		
Related Parties		

Aruneesh Panjra



Aruneesh Panjra
Yes

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 11 Inventories

(At lower of cost and net realisable value)

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
(a) Raw materials		
Goods-in-transit	-	-
(b) Work-in-progress @ (Refer Note below)		
Goods-in-transit	-	-
(c) Finished goods (other than those acquired for trading)	350.45	170.38
Goods-in-transit	-	-
	350.45	170.38
(d) Stock-in-trade (acquired for trading)	-	-
Goods-in-transit	-	-
	-	-
(e) Stores and spares		
Goods-in-transit	-	-
	-	-
Total	350.45	170.38

Asameen Farjat



Asameen Farjat
Har

Note 12 Trade receivables

		(Rs in Lakhs)	
Particulars	As at 31 March, 2022	As at 31 March, 2021	
	Amount	Amount	
Trade receivables outstanding for a period exceeding six months from the date they were due for payment			
Secured, considered good	-	-	
Unsecured, considered good	-	-	
Doubtful	-	-	
Less: Provision for doubtful trade receivables	-	-	
Other Trade receivables			
Secured, considered good	715.28	628.77	
Unsecured, considered good	-	-	
Doubtful	-	-	
Less: Provision for doubtful trade receivables	-	-	
	715.28	628.77	
Total	715.28	628.77	

Aswameesh Panjra



Aswameesh Panjra

Aswameesh Panjra

TRADE RECEIVABLE :

Sesderma India Pvt Ltd
Aniruddha Guria
Others

As at 31 March, 2022 vs at 31 March, 2021

	AMOUNT (RS.)	AMOUNT (RS.)
	715.28	628.77
	715.28	628.77

Trade Receivables ageing schedule as at 31st March,2022

(Rs in Lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables -considered good	715.28	-	-	-	-	715.28
(ii) Undisputed Trade receivables -considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	-	-	-	-

Trade Receivables ageing schedule as at 31st March,2022

(Rs. In Thousand)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables -considered good	628.77	-	-	-	-	628.77
(ii) Undisputed Trade receivables -considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	-	-	-	-

Asumeesh Garg

PRANJAN RATH & ASSOCIATES
Chartered Accountants
New Delhi

Asumeesh Garg

Hei

Note 13. Cash and cash equivalents

		(Rs in Lakhs)	
	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Cash in hand	2.63	1.43
	(b) Cheques, drafts on hand		
	(c) Balances with banks	70.01	15.36
	(d) Others (specify nature) (Sweep A/C)	-	-
	Total	72.64	16.78

Asmeesh Panjrat



Asmeesh Panjrat

For

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 14. Short-term loans and advances

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
(a) Loans and advances to employees		
Secured, considered good	-	-
Unsecured, considered good	-	-
Doubtful	-	-
	-	-
Less: Provision for doubtful loans and advances	-	-
(b) Prepaid expenses - Unsecured, considered good	-	-
(c) Balances with government authorities		
Unsecured, considered good		
(i) Gst credit receivable	-	1.15
(ii) TDS (A.Y. 2020-21)	-	0.02
(iii) TDS (A.Y. 2022-23)	16.69	-
(iv) Income Tax Refund	0.02	-
(d) Others - (Income Tax Refundable)		
Secured, considered good	-	-
Unsecured, considered good	-	-
Doubtful	-	-
	-	-
Less: Provision for other doubtful loans and advances	-	-
	-	-
Total	16.70	1.18

Detail of Prepaid Expenses

As at 31 March, 2022

As at 31 March, 2021

Amount (Rs.)

Amount (Rs.)

Prepaid Insurance

Prepaid Expenses

Security Deposits

-

Detail of Loan & Advances to Employees

As at 31 March, 2022

As at 31 March, 2021

Amount (Rs.)

Amount (Rs.)

Staff Advance- Employees

Staff Advance

-

Arun Prakash Jaiswal
Chartered Accountants
New Delhi

Arun Prakash Jaiswal

Note 15. Revenue from operations

(Rs in Lakhs)

		Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
			Amount	Amount
	(a)	Sale of products (Refer Note (i) below)	3,723.46	153.65
	(b)	Sale of services (Refer Note (ii) below)	647.30	-
	(c)	Other operating revenues (Refer Note (iii) below)	-	-
			4,370.76	153.65
		<u>Less:</u>		
	(d)	Excise duty	-	-
		Total	4,370.76	153.65

Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount	Amount
(i)	Sale of products comprises :		
	<u>Sales- Finsihed Goods</u>		
	Sales - semi finished goods	-	-
	Sales - parts of electric motors	-	-
	Total - Sale of manufactured goods	-	-
	<u>Sales- Finsihed Goods</u>		
	Sales - semi finished goods	-	-
	Sales - parts of electric motors	-	-
	Total - Sale of traded goods	-	-
	Total - Sale of products	-	-
(ii)	Sale of services comprises :		
	Total - Sale of services	-	-
(iii)	Other operating revenues comprise:		
	Sale of study material	-	-
	Duty drawback and other export incentives	-	-
	Labour Charges Received	-	-
	Freight & Cartage Charges Received	-	-
	Discount Received	-	-
	Total - Other operating revenues	-	-

Note 15.a Other Income

Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount	Amount
(i)	Dividend Income	0.17	0.21
(iv)	Interest Received	6.67	0.27
(v)	Other Income	2.48	-
	Total - Other Income	9.32	0.48

Arumesh Jain
Chartered Accountants
New Delhi

Anshu Jain
Officer

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 16.a Cost of materials consumed

(Rs in Lakhs)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Opening stock	-	-
Add: Purchases	-	-
Less: Closing stock	-	-
Cost of material consumed	-	-
Purchase A/c	-	-
Custom Duty	-	-
Freight and forwarding charges	-	-
Discount on Sales	-	-
logistics charges	-	-
Total	-	-

Note 16.b Purchase of traded goods

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Traded good	-	-
Opening stock	170.38	180.53
Add: Purchases	3,656.04	94.12
Add: Consumables	15.24	-
Add: Advertisement Expenses	653.69	-
Add: Marketing Expenses	26.12	-
Add: Discount Paid	14.30	-
Add: Courier Charges	49.34	-
Less: Closing stock	350.45	170.38
Total	4,234.67	104.26

Note 16.c Changes in inventories of finished goods, work-in-progress and Stores and spares

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
<u>Inventories at the end of the year:</u>		
Finished goods	-	-
Work-in-progress	-	-
Stores	-	-
	-	-
<u>Inventories at the beginning of the year:</u>		
Finished goods	-	-
Work-in-progress	-	-
Stock-in-trade	-	-
	-	-
Net (increase) / decrease	-	-

Aswameesh Jain

PRANJAN RATH & ASSOCIATES
Chartered Accountants
New Delhi

Aswameesh Jain

Aswameesh Jain

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 17 Employee benefits expense

(Rs in Lakhs)

	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Salaries and wages	27.39	30.72
	Contributions to provident and other funds	-	-
	Expense on employee stock option (ESOP) scheme	-	-
	Staff welfare expenses	9.92	-
	Total	37.31	30.72

Salaries and wages

	<u>AS AT 31.03.2022</u> <u>AMOUNT (RS.)</u>	<u>AS AT 31.03.2021</u> <u>AMOUNT (RS.)</u>
Salaries	26.82	18.72
Director Remuneration	-	12.00
Labour Charges	0.56	-
	27.39	30.72

Contributions to provident and other funds

	<u>AS AT 31.03.2022</u> <u>AMOUNT (RS.)</u>	<u>AS AT 31.03.2021</u> <u>AMOUNT (RS.)</u>
Employer Contribution(ESI)	-	-
Employer Contribution(PF)	-	-
Administrative Exps	-	-
	-	-

Arun Prakash Jaiswal



Arun Prakash Jaiswal

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 18 Finance costs

		(Rs in Lakhs)	
	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Interest expense on:		
	(i) Borrowings	0.46	0.62
	(ii) Trade payables	-	-
	(iii) Others	-	-
	- Interest on delayed / deferred payment of Sale tax	-	-
	(b) Other borrowing costs	0.14	0.03
	Total	0.60	0.65

Borrowing Cost

Interest on O/D
Interest on car loan

<u>As on 31.03.2022</u>	<u>As on 31.03.2021</u>
<u>Amount (Rs.)</u>	<u>Amount (Rs.)</u>
-	-
0.46	0.62
<u>0.46</u>	<u>0.62</u>

Other Borrowing Cost

Bank Charges

<u>As on 31.03.2022</u>	<u>As on 31.03.2021</u>
<u>Amount (Rs.)</u>	<u>Amount (Rs.)</u>
0.14	0.03
<u>0.14</u>	<u>0.03</u>

Arun Prakash Panjra



Arun Prakash Panjra

Note 19 Other expenses

Particulars	(Rs in Lakhs)	
	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount	Amount
Purchase of stores and spare parts	-	-
Purchase of packing materials	-	-
Software & Development Charges	0.30	0.53
Royalty Charges	-	-
Production Supervision Charges	-	-
Power & Fuel	3.03	0.35
Rent including lease rentals	4.20	-
Repairs and maintenance - Buildings	-	-
Repairs and maintenance - Machinery	-	-
Repairs and maintenance - Others	1.11	0.33
Insurance	2.04	0.74
Consumables	-	-
Travelling and conveyance	2.13	-
Printing and stationery	1.77	-
Freight and forwarding	0.37	-
Business promotion	-	0.54
Donations and contributions	-	-
Legal and professional	6.37	5.35
Payments to auditors (Refer Note (i) below)	-	-
Bad trade and other receivables, loans and advances written off	-	-
Loss on fixed assets sold / scrapped / written off	-	-
Miscellaneous expenses	29.52	2.85
Total	50.83	10.70

Note 27 Other expenses (contd.)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
(i) Payments to the auditors comprises (net of service tax input credit, where applicable):	-	-
As auditors - statutory audit	-	-
Reimbursement of expenses	-	-
Total	-	-

Detail of Rent

	AS AT 31.03.2022 AMOUNT (RS.)	AS AT 31.03.2021 AMOUNT (RS.)
Office rent	4.20	-
Warehouse Charges	-	-
	4.20	-

Detail of Repair & Maintenance of Machinery

	AS AT 31.03.2022 AMOUNT (RS.)	AS AT 31.03.2021 AMOUNT (RS.)
Repair & Maintenance	-	-

Detail of Insurance

	AS AT 31.03.2022 AMOUNT (RS.)	AS AT 31.03.2021 AMOUNT (RS.)
Vehicle Insurance	0.25	0.29
Other Insurance	1.79	0.45
	2.04	0.74

Detail of Legal & professional Charges

	AS AT 31.03.2022 AMOUNT (RS.)	AS AT 31.03.2021 AMOUNT (RS.)
Professional Charges	6.37	5.35
Accounting Charges	-	-
Professional Charges O/S India	-	-
	6.37	5.35

Miscellaneous Expenses

	AS AT 31.03.2022 AMOUNT (RS.)	AS AT 31.03.2021 AMOUNT (RS.)
Amc Charges	0.09	-
Transportation Charges	0.81	-
General Expenses	0.10	0.40
Telephone Expenses	5.83	0.37
Vehicle running and maintenance	1.20	1.37
Hotel expenses	0.04	0.31
Festival Expense	10.83	-
Courier Expenses	-	0.18
CRM Expenses	1.02	-
Office Expenses	9.61	0.22
Labour Charges	-	-
	29.52	2.85

19.6 Corporate social n Relevant CARO 21 (Rs in Lakhs)

Sr. No.	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
1	Amount required to	N.A	N.A
2	Amount of expenditure	N.A	N.A
3	Shortfall at the end	N.A	N.A
4	Total of previous year	N.A	N.A
	Total	-	-

19.6.1


a
b
c
d

Other disclosures

Reason for shortfall
Nature of CSR activities
Details of related party transactions *
Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately.

* e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,

Amresh Jain



Amresh Jain

OK
Chakrabarti



Assured by my self

Sr. No.	Particulars	2021-22		2020-21	
		2021-22	2020-21	2021-22	2020-21
1	Interest Expenses	-	-	-	-
2	Salary Expenses	-	-	-	-
Total		-	-	-	-

Transactions with related parties for the year ended March 31, 2022
(Rs. in Lakhs)

Sr. No.	Name	Relation
1		
2		
3		
4		
5		
6		
7		
8		

Names of related parties and description of relationship :
Relevant Para of the CARO 2020 - 3(xiii)

Note 20 Disclosures under Accounting Standards (contd.)

Note	Particulars	(Rs In Lakhs)	
		For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Earnings per share		
	Basic		
20.a	Continuing operations		
	Net profit / (loss) for the year from continuing operations	38.56	2.12
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders	38.56	2.12
	Weighted average number of equity shares	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share from continuing operations - Basic	385.56	21.19
20.b	Total operations		
	Net profit / (loss) for the year	38.56	2.12
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders	38.56	2.12
	Weighted average number of equity shares	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share - Basic	385.56	21.19
20.c	Basic (excluding extraordinary items)		
	Continuing operations		
	Net profit / (loss) for the year from continuing operations	38.56	2.12
	(Add) / Less: Extraordinary items (net of tax) relating to continuing operations	-	-
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders, excluding extraordinary items	38.56	2.12
	Weighted average number of equity shares	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share from continuing operations, excluding extraordinary items - Basic	385.56	21.19
20.d	Total operations		
	Net profit / (loss) for the year	38.56	2.12
	(Add) / Less: Extraordinary items (net of tax)	-	-
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders, excluding extraordinary items	38.56	2.12
	Weighted average number of equity shares	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share, excluding extraordinary items - Basic	385.56	21.19
	Diluted		
	The diluted earnings per share has been computed by dividing the Net Profit After Tax available for Equity Shareholders by the weighted average number of equity shares, after giving dilutive effect of the outstanding Warrants, Stock Options and Convertible bonds for the respective periods. Since, the effect of the conversion of Preference shares was anti-dilutive, it has been ignored.		
20.e	Continuing operations		
	Net profit / (loss) for the year from continuing operations	38.56	2.12
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders from continuing operations	38.56	2.12
	Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
	Profit / (loss) attributable to equity shareholders from continuing operations (on dilution)	38.56	2.12
	Weighted average number of equity shares for Basic EPS	0.10	0.10
	Add: Effect of warrants, ESOPs and Convertible bonds which are dilutive	-	-
	Weighted average number of equity shares - for diluted EPS	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share, from continuing operations - Diluted	385.56	21.19

Note 20 Disclosures under Accounting Standards (contd.)

Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
		Amount (Rs.)	Amount (Rs.)
20.f	Total operations		
	Net profit / (loss) for the year	38.56	2.12
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders	38.56	2.12
	Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
	Profit / (loss) attributable to equity shareholders (on dilution)	38.56	2.12
	Weighted average number of equity shares for Basic EPS	0.10	0.10
	Add: Effect of Warrants, ESOPs and Convertible bonds which are dilutive	-	-
	Weighted average number of equity shares - for diluted EPS	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share - Diluted	385.56	21.19
20.g	Diluted (excluding extraordinary items)		
	Continuing operations		
	Net profit / (loss) for the year from continuing operations	38.56	2.12
	(Add) / Less: Extraordinary items (net of tax)	-	-
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders, excluding extraordinary items	38.56	2.12
	Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
	Profit / (loss) from continuing operations attributable to equity shareholders (on dilution)	38.56	2.12
	Weighted average number of equity shares for Basic EPS	0.10	0.10
	Add: Effect of Warrants, ESOPs and Convertible bonds which are dilutive	-	-
	Weighted average number of equity shares - for diluted EPS	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share, from continuing operations, excluding extraordinary items - Diluted	385.56	21.19
20.h	Total operations		
	Net profit / (loss) for the year	38.56	2.12
	(Add) / Less: Extraordinary items (net of tax)	-	-
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders, excluding extraordinary items	38.56	2.12
	Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
	Profit / (loss) attributable to equity shareholders (on dilution)	38.56	2.12
	Weighted average number of equity shares for Basic EPS	0.10	0.10
	Add: Effect of Warrants, ESOPs and Convertible bonds which are dilutive	-	-
	Weighted average number of equity shares - for diluted EPS	0.10	0.10
	Par value per share	0.00	0.00
	Earnings per share, excluding extraordinary items - Diluted	385.56	21.19

Asameesh Jain



Asameesh Jain

Asameesh Jain

Relevant Para of the CARO 2020 - 3(xix)
(Rs in Lakhs)

Numerator	2021-2022	2020-2021	Denominator	2021-2022	2020-2021	31-Mar-22	31-Mar-21
Current Assets			Current Liabilities				
Inventories	350	170	Creditors for goods and services	1,985	-		
Sundry Debtors	715	629	Short term loans	4	6		
Cash and Bank balances	73	17	Bank Overdraft				
Receivables/Accruals	-	-	Cash Credit				
Loans and Advances	32	54	Outstanding Expenses				
Disposable Investments			Provision for taxation	13	1		
Any other current assets			Proposed dividend				
			Unclaimed Dividend	25	2		
	1,171	870	Any other current liabilities	2,028	9	0.58	95.31
Total Liabilities			Shareholder's Equity				
Total Outside Liabilities	4	6	Total Shareholders' Equity	141	103	0.03	0.06
Net Operating Income	57	8	Debt Service	4	6	14.54	1.22
Net Profit after tax + non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of fixed assets			Current Debt Obligation (Interest & Lease payment + Principal Repayment)				
Profit for the period			Avg. Shareholders' Equity				
Net Profit after taxes - preference dividend (if any)	39	2	(Beginning shareholders' equity + Ending shareholders' equity) / 2	122	103	31.64%	2.07%
Cost of Goods sold			Average Inventory				
(Opening Stock + Purchases) - Closing Stock			(Opening Stock + Closing Stock) / 2	260	175		
Net Credit Sales			Average Trade Receivables				
Credit Sales	4,371	154	(Beginning Trade Receivables + Ending Trade Receivables) / 2	672	629	7	0
Total Purchases			Average Trade Payables				
Annual Net Credit Purchases	9,575	8,162	(Beginning Trade Payables + Ending Trade Payables) / 2	1,604	1,224	5.97	6.67
Net Sales			Average Working Capital				
Total Sales - Sales Return	4,371	154	Current Assets - Current Liabilities	(857)	861	(5.10)	0.18
Net Profit			Net Sales				
Profit After Tax	39	2	Sales	4,371	154	0.88%	1.38%
EBIT			Capital Employed				
Profit before Interest and Taxes	52	3	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability	145	109	35.55%	2.63%
Return/Profit/Earnings	39	2	Investment **	465	-	0.08	#DIV/0!

could be treated three ways

Current Liabilities
Working Capital
Term Debt

$TV(T0) = \sum (IC(t))$

d of time period

$T0$ = Beginning of time period

= Specific date falling between $T1$ and $T0$

$4V(T1)$ = Market Value at $T1$

$4V(T0)$ = Market Value at $T0$

$2(t)$ = Cash inflow, cash outflow on specific date

$W(t)$ = Weight of the net cash flow (i.e. either net inflow or net outflow) on day 't', calculated as $(T1 - t) / T1$

* provide ROI separately for each asset class (e.g., equity, fixed income, money market, etc.).

Arunesh Panjra



Arunesh Panjra

JP

IV. Additional Regulatory Info

Where the Company has revalued its Property, Plant and Equipment, the company shall disclose as to whether the revaluation is based on the valuation by a registered valuer as defined under rule 2 of the Companies (Registered Valuers and Valuation) Rules, 2017

Details of Benami Property held

Where any proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder, the company shall disclose the following:-

- Details of such property, including year of acquisition,
- Amount thereof,
- Details of Beneficiaries,
- If property is in the books, then reference to the item in the Balance Sheet,
- If property is not in the books, then the fact shall be stated with reasons,
- Where there are proceedings against the company under this law as an abettor of the transaction or as the transferor then the details shall be provided,
- Nature of proceedings, status of same and company's view on same.

Where the Company has borrowings from banks or financial institutions on the basis of security of current assets, it shall disclose the following:-

- whether quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts,
- If not, summary of reconciliation and reasons of material discrepancies, if any to be adequately disclosed.

Willful Defaulter*

Where a company is a declared wilful defaulter by any bank or financial Institution or other lender, following details shall be given:-

- Date of declaration as wilful defaulter,
- Details of defaults (amount and nature of defaults),

* "wilful defaulter" here means a person or an issuer who or which is categorized as a wilful defaulter by any bank or financial institution (as defined under the Act) or consortium thereof, in accordance with the guidelines on wilful defaulters issued by

Relationship with struck off companies

of struck	transactions with struck off	Outstanding	with struck off company, if any,
	Investment in securities		
	Receivables		
	Payables		
	Shares held by struck		
	Other outstanding		

Registration of charges or satisfaction with Registrar of Companies

Where any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period, details and reasons thereof shall be disclosed.

Compliance with number of layers of companies

Where the company has not complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017, the name and CIN of the companies beyond the specified layers and the relationship/extent of holding of the company in such downstream companies shall be disclosed.

Following Ratios to be disclosed:-

- Current Ratio,
- Debt-Equity Ratio,
- Debt Service Coverage Ratio,
- Return on Equity Ratio,
- Inventory turnover ratio,
- Trade Receivables turnover ratio,
- Trade payables turnover ratio,
- Net capital turnover ratio,
- Net profit ratio,
- Return on Capital employed,
- Return on investment.

The company shall explain the items included in numerator and denominator for computing the above ratios. Further explanation shall be provided for any change in the ratio by more than 25% as compared to the preceding year.

Compliance with approved Scheme(s) of Arrangements

Where any Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013, the Company shall disclose that the effect of such Scheme of Arrangements have been accounted for in the books of account of the Company 'in accordance with the Scheme' and 'in accordance with accounting standards' and deviation in this regard shall be explained.

Utilisation of Borrowed funds and share premium:

(A) Where company has advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall

- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries;

the company shall disclose the following:-

- date and amount of fund advanced or loaned or invested in Intermediaries with complete details of each Intermediary.
- date and amount of fund further advanced or loaned or invested by such Intermediaries to other intermediaries or Ultimate Beneficiaries along with complete details of the ultimate beneficiaries.
- date and amount of guarantee, security or the like provided to or on behalf of the Ultimate Beneficiaries
- declaration that relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999) and Companies Act has been complied with for such transactions and the transactions are not violative of the Prevention of Money-Laundering act, 2002 (15 of 2003);

(B) Where a company has received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall

- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries, the company shall disclose the following:-
- date and amount of fund received from Funding parties with complete details of each Funding party.
- date and amount of fund further advanced or loaned or invested by other intermediaries or Ultimate Beneficiaries along with complete details of the other intermediaries' or ultimate beneficiaries.
- date and amount of guarantee, security or the like provided to or on behalf of the Ultimate Beneficiaries
- declaration that relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999) and Companies Act has been complied with for such transactions and the transactions are not violative of the Prevention of Money-Laundering act, 2002 (15 of 2003);

Aswameesh Panjraan



Aswameesh Panjraan

Aswameesh Panjraan

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

DEFERRED TAX

(Rs in Lakhs)

Net Block as per Companies Act as on 31/03/2022	205.28
Net Block as per Income Tax as on 31-03-2022	209.58
(DTA)/DTL	<u>(4.29)</u>
Rounded off	(4.29)
Tax	(1.08)
Add : Surcharge	<u>-</u>
Deffered Tax Assets	(1.08)
less:- last year DTL/DTA	<u>(0.77)</u>
Tfd to Profit & Loss Appro. A\C	<u><u>(0.31)</u></u>

Asuneesh Panjrat



Asuneesh Panjrat

Har

Notes to the Financial Statements

1. Summary of Significant Accounting Policies

1.1 General Information

The company is primarily in the business of pharmaceuticals.

1.2 Basis for Preparation of Financial Statements

These financial statements have been prepared as a going concern in accordance with the generally accepted accounting principal in India under the historical cost convention on accrual basis and comply in all material aspects with the Companies Act, 2013, applicable rules and other relevant provision of the Companies Act, 2013 and Accounting Standard 30, Financial Instruments: Recognition and measurements issued by the Institute of Chartered Accountants of India to the extent it does not contradict with any other accounting standard referred to in the Companies Act, 2013.

All assets and liabilities have been classified as current or non-current according to the Company's operating cycle and other criteria set out in the Companies Act, 2013. Based on the nature of product and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – noncurrent classification of assets and liabilities.

1.3 Revenue Recognition

Income is recognised on completion of sales and rendering of services.

1.4 Fixed Assets

Tangible Assets

- a) Fixed assets are carried at cost of acquisition or construction or at manufacturing cost (in case of own manufactured assets) in the year of capitalisation less accumulated assets) in the year of capitalisation less accumulated depreciation.
- b) Assets acquire under finance lease are capitalised at the lower of their fair value of minimum lease payments.

1.5 Borrowing Costs

Borrowing cost in machinery and vehicles are debited to Profit and Loss Account.

1.6 Depreciation/ Amortisation

Depreciation has been provided in accordance with useful lives prescribed in the Companies Act, 2013 on written down value basis.

1.7 Inventories

- a) Inventories are valued at the lower of cost, determined on the weighted average basis and net realisable value.

1.8 Taxes

Tax expenses for the year, comprising current tax and deferred tax, is included in determining the net profit or loss for the year.

Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act and at the prevailing tax rates.

Deferred tax is recognised for all timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In Situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each balance sheet date, the Company reassesses unrecognised deferred tax assets, if any

Minimum Alternative Tax (MAT), paid in accordance with the Income Tax Act, 1961 gives rise to expected future economic benefit in the form of adjustment of future tax liability arising within a specified period, is recognised as an asset only to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. Such asset is reviewed at each balance sheet date and the carrying amount of the MAT credit asset is written down to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during specified period.

1.9 Provisions and Contingencies

Provisions: Provisions are recognised when there is a present obligation as result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the balance sheet date and are not discounted to their present value.

Contingent Liabilities: Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence on non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

1.10 Cash and Cash Equivalent

In the Financial Statement, cash and cash equivalent include cash in hand, demand deposit with bank, and other short-term highly liquid investment with original maturities of three months or less.

1.11 Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share consist of the net profit for the period and any attributable tax thereon. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events other than the conversion of potential equity share that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.



K R A & CO.

Chartered Accountants

011 - 47082855
Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **SATNAM MEDICAL AGENCIES PRIVATE LIMITED** ("hereinafter referred to as the 'Holding Company'") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated balance sheet as at March 31, 2022, and the consolidated statement of profit and loss, and the consolidated cash flow statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit, and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the director's report, management discussion and analysis and report on corporate governance, but does not include the financial statements and our auditor's report thereon. The director's report, management discussion and analysis and report on corporate governance are expected to be made available to us after the date of this auditor's report. Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other



information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. There are no key audit matters to communicate

Other Matter

The consolidated financial statements of the Group for the financial year ended 31 March 2022 will be filed with the relevant authorities during the current financial year 2025–26, resulting in delay in statutory filing under the Companies Act, 2013. The Holding Company and certain subsidiaries have compounded the delay and paid the applicable compounding fees and penalties, which are material in amount and have been duly recognized in the consolidated financial statements for the year ended 31 March 2026.

Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under section 133 of the Act. The respective Management and Board of Directors of the Companies Included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the each Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the Companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



The respective Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in section titled 'Other Matters' in this audit report. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors and management certified accounts as referred to in Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the books of account



- d. In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company did not have any pending litigations for which there were any impact on its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For KRA & Co.
Chartered Accountants
(Firm Registration No.020266N)


Rajat Goyal
Partner
Membership No.: 503150
UDIN: 26503150GHLUER7524
Place: Delhi
Date:02/03/2026

ANNEXURE "A" TO THE INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SATNAM MEDICAL AGENCIES PRIVATE LIMITED

(Referred to in Paragraph 1 point (f) under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of **SATNAM MEDICAL AGENCIES PRIVATE LIMITED** (the 'Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as the 'Group') as at and for the year ended 31 March 2022, we have audited the internal financial controls over financial reporting ('IFCoFR') of the Holding Company, its subsidiary company, which are companies covered under the Act, as at that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company, its subsidiary company, which are companies covered under the Act, as at that date, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India (the 'ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the company's business, including adherence to the company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the IFCoFR of the Holding Company, its subsidiary company, which are companies covered under the Act, as at that date, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of IFCoFR, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate IFCoFR were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the IFCoFR and their operating effectiveness. Our audit of IFCoFR includes obtaining an understanding of IFCoFR, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the



auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the IFCoFR of the Holding Company, its subsidiary company as aforesaid.

Meaning of Internal Financial Controls over Financial Reporting

A company's IFCoFR is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's IFCoFR include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements


Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of IFCoFR, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the IFCoFR to future periods are subject to the risk that the IFCoFR may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company, its subsidiary company, which are companies covered under the Act, have in all material respects, adequate internal financial controls over financial reporting and such controls were operating effectively as at 31 March 2022, based on the internal control over financial reporting criteria established by the Holding Company, its subsidiary company as aforesaid, considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India

For KRA & Co.
Chartered Accountants
(Firm Registration No.020266N)



Rajat Goyal
Partner
Membership No.: 503150
UDIN: 26503150GHLUER7524
Place: Delhi
Date: 02/03/2026

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
1704 PVT SHOP NO. 1 FF BHAGIRATH PALACE CHANDANI CHOWK DELHI

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs in Lakh)

Particulars		Note No.	As at 31 March, 2022	As at 31 March, 2021
A	Equity and Liabilities			
	Shareholders' Funds			
	(a) Share Capital	1	10.38	10.38
	(b) Reserves And Surplus	2	56.80	49.49
			67.17	59.87
	Share Application Money Pending Allotment		60.45	60.45
	Current Liabilities			
	(a) Short-Term Borrowings	3	3.90	6.41
	(b) Trade Payables			
	Total outstanding dues of micro enterprises and small enterprises; and	4	1968.16	1249.14
	Total outstanding dues of creditors other than micro enterprises and small enterprises	4	-	-
	(c) Other Current Liabilities	5	25.42	1.82
	(d) Short-Term Provisions	6	13.31	0.90
			2010.79	1258.27
	TOTAL		2138.41	1378.58
B	Assets			
	Non-Current Assets			
	(a) Property, Plant And Equipment And Intangible Assets	7		
	(I) Property, Plant And Equipment		207.21	211.27
	(II) Intangible Assets		0.31	0.39
			207.52	211.66
	(b) Non-Current Investments	8	81.00	103.80
	(c) Deferred Tax Assets (Net)	21	1.08	0.77
	(d) Long-Term Loans And Advances	9	15.67	47.52
			97.75	152.09
	Current Assets			
	(a) Current Investments	10	464.55	-
	(b) Inventories	11	444.11	249.89
	(c) Trade Receivables	12	827.75	722.51
	(d) Cash And Cash Equivalents	13	80.02	36.26
	(e) Short-Term Loans And Advances	14	16.70	6.18
			1833.14	1014.83
	TOTAL		2138.41	1378.58
	Notes to Accounts forming integral part of Financial Statements	23		

IN TERMS OF OUR SEPARATE AUDIT REPORT OF EVEN DATE ATTACHED

For KRA & Co.

Chartered Accountants

FRN:020266N

CA Rajat Goyal
M. NO 503150 020266N
Place : New Delhi
UDIN :- 265031506HLUER7524
Date : 02/03/2026

For and on behalf of the Board of Directors

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Rishabh Jain
Director
RISHABH JAIN
5276845

Nitin Jain
Director
NITIN JAIN
05276862

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
CONSOLIDATED STATEMENT OF PROFIT & LOSS

(Rs in Lakh)

Particulars	Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
Revenue			
Revenue from Operations	15	4559.68	3535.22
Other Income	16	16.33	50.38
Total Revenue		4576.01	3585.60
Expenses			
Cost of Materials Consumed	17	103.69	2308.99
Purchase of Traded Goods	18	4234.67	104.26
Employee Benefits Expense	19	69.97	440.84
Finance Costs	20	0.60	4.45
Depreciation And Amortisation Expense	7	6.67	8.39
Other Expenses	21	113.83	586.64
Total Expenses		4529.43	3453.58
Profit / (Loss) before Tax		46.58	132.02
Tax Expense:			
Current Tax Expense		13.31	8.46
Deferred Tax		(0.31)	(0.01)
Profit / (Loss) for the year		33.58	123.56
Add: Profit from Associate		10.29	10.80
Profit / (Loss) for the year		43.87	134.36

Particulars	Note No.	For the year ended 31 March, 2022 Amount (Rs.)	For the year ended 31 March, 2021 Amount (Rs.)
Earnings per share (of ' Rs. 10/- each):			
(a) Basic			
(i) Continuing operations	22.a	365.12	1,343.62
(b) Diluted			
(i) Continuing operations	22.e	365.12	1,343.62
Notes to Accounts forming integral part of Financial Statements IN TERMS OF OUR SEPARATE AUDIT REPORT OF EVEN DATE ATTACHED For KRA & Co. Chartered Accountants FRN:020266N  CA Rajat Goyal Partner M. NO. 503150 Place : New Delhi UDIN:- 26503150G+HLUER7524 Date : 02/03/2026			
For and on behalf of the Board of Directors of SATNAM MEDICAL AGENCIES PRIVATE LIMITED  Director RISHABH JAIN 5276845  Director NITIN JAIN 05276862			

SATNAM MEDICAL AGENCIES PRIVATE LIMITED
STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31 MARCH, 2022

CONSOLIDATED CASH FLOW STATEMENT

(Rs in Lakhs)

Particulars	For the Year ended March 31, 2022	For the year ended March 31, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	46.58	132.02
Adjustments for:		
Share of (Profit) / Loss of Associates	(10.29)	(10.80)
Depreciation and amortisation expense	6.67	8.39
Finance Cost	0.60	4.45
Discount Received	(0.17)	(0.21)
Interest Income	(6.67)	(0.27)
Operating profit / (loss) before working capital changes	36.71	133.57
Changes in working capital:		
(Decrease) / Increase in Provisions	12.41	(7.13)
Increase / (Decrease) in Trade Payables	719.02	(850.19)
Increase in Other Current Liabilities	11.43	(14.64)
(Increase) / Decrease in trade receivables	(105.24)	342.41
Decrease / (Increase) in Inventories	(194.22)	403.99
Decrease in other Loan & Advances	21.33	37.79
CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	501.42	45.81
Less: Taxes paid	(13.31)	(8.46)
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	488.11	37.34
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible / intangible assets	(2.53)	(172.34)
(Increase) / Decrease in Non-Current Investments	22.79	48.33
(Increase) / Decrease in Current Investments	(464.55)	-
Discount Received	0.17	0.21
Interest income received	6.67	0.27
NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES	(437.43)	(123.53)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds/(Repayment) from short-term borrowings	(2.51)	(17.55)
Finance Cost	(0.60)	(4.45)
Increase/(Decrease) in Long-Term Borrowing	-	-
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	(3.11)	(21.99)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	47.57	(108.18)
Cash and Cash equivalents at beginning period	36.26	139.62
Foreign Exchange Reserve	(3.81)	4.82
Cash and Cash equivalents at end of period	80.02	36.26
D. Cash and Cash equivalents comprise of		
Cash on hand	10.02	20.91
Balances with banks		
In current accounts	70.01	15.36
Total	80.02	36.26

This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"

Significant accounting policies

Notes referred to above form an integral part of the Financial Statements.

For KRA & Co.

Chartered Accountants

FRN:020266N


CA Rajat Goyal
M. NO 503150


Place : New Delhi

UDIN :- 26503150G+HLUER7524

Date : 02/03/2026

For and on behalf of the Board of Directors

SATNAM MEDICAL AGENCIES PRIVATE LIMITED


Director
RISHABH JAIN
5276845


Director
NITIN JAIN
05276862

SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 1 Share capital

(Rs in Lakhs)					
	Particulars	As at 31 March, 2022		As at 31 March, 2021	
		Number of shares	Amount	Number of shares	Amount
	(a) Authorised Equity shares of Rs.10 each with voting rights	10,10,000	101.00	10,10,000	101.00
	(b) Issued Equity shares of Rs.10 each with voting rights	1,03,750	10.38	1,03,750	10.38
	(c) Subscribed and fully paid up Equity shares of Rs.10 each with voting rights	1,03,750	10.38	1,03,750	10.38
	Total	1,03,750	10,37,500.00	1,03,750	10,37,500.00
i	The Company has only Equity Share capital. The Equity Shares has been further bifurcated in to Authorised, Issued, Subscribed and Paid Equity capital.				

	Particulars					
Notes:						
(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period: 31.03.2022						
Details of Equity Shares separately for Issued, Subscribed and fully paid up and Subscribed but not fully paid up, as applicable.						
	Particulars	Opening Balance	Fresh issue	Bonus	others i.e.Esop/Conversion/ Buy Back	Closing Balance
	Equity shares with voting rights					
	Year ended 31 March, 2018					
	- Number of shares	10,000	-	-	-	10,000
	- Amount (Rs. 10/- per share)	1,00,000	-	-	-	10,000
	Year ended 31 March, 2019					
	- Number of shares	10,000	93,750.00	-	-	1,03,750
	- Amount (Rs. 10/- per share)	1,00,000	9,37,500.00	-	-	10,37,500

Shares held by promoters at the end of the year 31st March 2022					% Change during the year***
Sr. No.	Promoter Name	No. of Shares**	% of total shares**		
1	SHIVANI JAIN	93750	90.36%		0.00%
2	PRAVEEN JAIN	0	0%		-100%
3	NITIN JAIN	7600	7.33%		46.15%
4	RISHAB JAIN	2400	2.31%		0.00%
	Total	1,03,750	7%		

Shares held by promoters at the end of the year ending 31st March 2021					% Change during the year***
Sr. No.	Promoter Name	No. of Shares**	% of total shares**		
1	SHIVANI JAIN	93750	90.36%		-
2	PRAVEEN JAIN	2400	0%		-
3	NITIN JAIN	5200	7%		-
4	RISHAB JAIN	2400	2.31%		-
	Total	1,03,750	7%		



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 2 Reserves and Surplus

(Rs in Lakh)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(c) Securities premium account		
	Opening balance	65.63	65.63
	Add : Premium on shares issued during the year	-	-
	Closing balance	65.63	65.63
	(i) Surplus / (Deficit) in Statement of Profit and Loss		
	Opening balance	(48.88)	(155.13)
	Add: Profit / (Loss) for the year	43.87	134.36
	Closing balance	(5.02)	(20.76)
	Add: Foreign Exchange Reserve	(3.81)	4.63
	Total	56.80	49.49



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 3. Short-term borrowings**(Rs in Lakh)**

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Loans repayable on demand		
	From banks		
	Secured	3.90	6.41
	Total	3.90	6.41



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 4. Trade payables**(Rs in Lakhs)**

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Trade payables:		
	Trade payables:	1962.02	1247.08
	Other payables	6.15	2.06
	Total	1968.16	1249.14



SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 5. Other current liabilities

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Statutory remittances	21.22	1.82
	Others (Expenses Payable)	4.20	-
	Total	25.42	1.82



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 6. Short-term provisions

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(i) Provision for tax (A/Y 2022-23)	13.31	-
	(ii) Provision for tax (A/Y 2021-22)	-	0.90
	Total	13.31	0.90



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 7. Fixed assets

(Rs in Lakhs)

	Fixed Assets	PERIOD	Rate of Dep.	Gross Block					Accumulated Depreciation					Net Block	
				Balance as at 1st April 2021	Additions	(Disposals)	Exchange difference	Balance as at 31st March 2022	Balance as at 1st April 2021	Depreciation charge for the year	Exchange difference	On disposals	Balance as at 31st March 2022	Balance as at 31st March 2021	Balance as at 31st March 2022
a	Tangible Assets														
	Car	8	11.88%	30.93	-	-	-	30.93	16.90	3.67	-	-	20.57	14.03	10.36
	Airconditioner	10	9.50%	1.32	-	-	-	1.32	0.52	0.13	-	-	0.64	0.80	0.68
	Computer	6	15.83%	3.51	-	-	-	3.51	2.20	0.56	-	-	2.75	1.31	0.75
	Printer	6	15.83%	0.10	-	-	-	0.10	0.05	0.02	-	-	0.07	0.04	0.03
	Mobile Phone	8	11.88%	2.56	-	-	-	2.56	0.58	0.30	-	-	0.89	1.98	1.68
	Furniture & Fittings	10	9.50%	10.22	2.57	-	(0.11)	12.68	4.49	1.92	(0.07)	-	6.33	5.73	6.34
	Land		0.00%	187.38	-	-	-	187.38	-	-	-	-	-	187.38	187.38
	Total			236.01	2.57	-	(0.11)	238.47	24.74	6.59	(0.07)	-	31.26	211.27	207.21
b	Intangible Assets														
	Others		25.89%	0.39	-	-	(0.01)	0.39	-	0.08	(0.00)	-	0.08	0.39	0.31
	Total			0.39	-	-	(0.01)	0.39	-	0.08	(0.00)	-	0.08	0.39	0.31
	Total			236.41	-	-	(0.13)	238.86	24.74	6.67	(0.07)	-	31.34	211.66	207.52



SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 8 Non-Current Investments

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Investments in Iberia SkinBrands India Pvt. Ltd. (India)	19.29	41.75
	PHEASANTZ PHARMA SOLUTIONS PRIVATE LIMITED	61.71	62.04
		-	-
	Total	81.00	103.80

Note 10 Current Investments

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Sweep A/c	464.55	-
	Total	464.55	-



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 9 Long-term loans and advances

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(i) Security Deposit		
	Secured, considered good	3.65	
	Unsecured, considered good	10.02	17.52
	Doubtful	-	-
		13.67	17.52
	Less: Provision for doubtful deposits	-	-
		13.67	17.52
	(b) Advance income tax (net of provisions) - Unsecured, considered good		
	For the A/Y- 2022-23	2.00	
	(c) Other loans and advances (specify nature)		
	Secured, considered good		
	Unsecured, considered good	-	30.00
	Doubtful	-	30.00
		-	-
	Less: Provision for other doubtful loans and advances	-	30.00
		-	-
	Total	15.67	47.52



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 11 Inventories

(At lower of cost and net realisable value)

(Rs in Lakhs)

	Particulars	As at 31 March, 2022	As at 31 March, 2021
	(a) Finished goods (other than those acquired for trading)	444.11	249.89
	Goods-in-transit	-	-
	Total	444.11	249.89



SATNAM MEDICAL AGENCIES PRIVATE LIMITED
Notes forming part of the financial statements

Note 12 Trade receivables

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount	Amount
Trade receivables outstanding for a period exceeding six months from the date they were due for payment		
Secured, considered good	112.47	93.74
Unsecured, considered good	-	-
Doubtful	-	-
	112.47	93.74
Less: Provision for doubtful trade receivables	-	-
	112.47	93.74
Other Trade receivables		
Secured, considered good	715.28	628.77
Unsecured, considered good	-	-
Doubtful	-	-
	715.28	628.77
Less: Provision for doubtful trade receivables	-	-
	715.28	628.77
Total	827.75	722.51



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 13. Cash and cash equivalents

(Rs in Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
(a) Cash in hand	10.02	20.91
(b) Cheques, drafts on hand	-	-
(c) Balances with banks	70.01	15.36
(d) Others (specify nature) (Sweep A/C)	-	-
Total	80.02	36.26



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 14. Short-term loans and advances**(Rs in Lakhs)**

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
(a) Prepaid expenses - Unsecured, considered good		5.00
(b) Balances with government authorities		
Unsecured, considered good	-	
(i) Gst credit receivable	-	1.15
(ii) TDS (A.Y. 2020-21)	-	0.02
(iii) TDS (A.Y. 2022-23)	16.69	-
(iv) Income Tax Refund	0.02	-
Total	16.70	6.18



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 15. Revenue from operations

(Rs in Lakhs)

		Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
			Amount	Amount
	(a)	Sale of products (Refer Note (i) below)	3912.38	3524.40
	(b)	Sale of services (Refer Note (ii) below)	647.30	-
	(c)	Other operating revenues (Refer Note (iii) below)	-	10.82
		Total	4559.68	3535.22

Note 16 Other Income

(Rs in Lakhs)

	Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
			Amount	Amount
	(i)	Dividend Income	0.17	0.21
	(ii)	Interest Received	6.67	0.27
	(iii)	Other Income	9.49	49.90
		Total - Other Income	16.33	50.38



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 17 Cost of materials consumed

(Rs in Lakhs)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Opening stock	79.50	409.84
Add: Purchases	91.51	2357.51
Add: Direct Cost	26.35	294.62
	197.36	3061.97
Less: Closing stock	93.67	752.97
Cost of material consumed	103.69	2308.99

Note 18 Purchase of traded goods

(Rs in Lakhs)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount (Rs.)	Amount (Rs.)
Traded good		
Opening stock	170.38	180.53
Add: Purchases	3656.04	94.12
Add: Consumables	15.24	-
Add: Advertisement Expenses	653.69	-
Add: Marketing Expenses	26.12	-
Add: Discount Paid	14.30	-
Add: Courier Charges	49.34	-
Less: Closing stock	350.45	170.38
Total	4234.67	104.26



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 19 Employee benefits expense

(Rs in Lakhs)

	Particulars	For the year ended 31	For the year ended 31
		March, 2022	March, 2021
	Salaries and wages	56.97	408.07
	Contributions to provident and other funds	3.08	12.00
	Expense on employee stock option (ESOP) scheme	-	19.41
	Staff welfare expenses	9.92	1.36
	Total	69.97	440.84



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 20 Finance costs

(Rs in Lakhs)

	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	(a) Interest expense on:	-	-
	(i) Borrowings	0.46	1.46
	(b) Other borrowing costs	0.14	1.97
		-	1.02
	Total	0.60	4.45



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 21 Other expenses

(Rs in Lakhs)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	Amount	Amount
Printing & Development Charges	-	5.19
Office Expenses	-	9.14
Light and heat	1.07	-
Water rates	0.10	-
Printing, postage and stationery	1.20	-
Advertising and marketing costs	0.17	210.85
Telecommunications and data costs	3.10	3.35
Accountancy fees	2.45	1.25
Commissions Payable	30.58	32.01
Bank charges	0.47	-
Repairs and maintenance	0.18	-
Professional fees	0.45	-
Cleaning	0.08	-
Subcontractor costs	13.23	-
Software & Development Charges	0.30	0.53
Royalty Charges	-	-
Production Supervision Charges	-	-
Power & Fuel	3.03	1.83
Rent including lease rentals	4.20	29.48
Repairs and maintenance - Others	1.11	8.83
Computer and IT consumables	-	0.37
Insurance	2.04	11.04
Consumables	-	-
Travelling and conveyance	2.13	26.71
Printing and stationery	1.77	3.49
Office rent	9.54	-
Repair & Maintenance	0.38	-
Freight and forwarding	0.37	-
Business promotion	-	8.24
Legal and professional	6.37	49.72
Miscellaneous expenses	29.52	184.61
Total	113.83	586.64



SATNAM MEDICAL AGENCIES PRIVATE LIMITED

Notes forming part of the financial statements

Note 22 Disclosures under Accounting Standards (contd.)

		(Rs in lakhs)	
Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		Amount (Rs.)	Amount (Rs.)
	Earnings per share		
	<u>Basic</u>		
22.a	<u>Continuing operations</u>		
	Net profit / (loss) for the year from continuing operations	36.51	134.36
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders	36.51	134.36
	Weighted average number of equity shares	10,000.00	10,000.00
	Par value per share	10.00	10.00
	Earnings per share from continuing operations - Basic	365.12	1,343.62
22.b	<u>Diluted</u>		
	The diluted earnings per share has been computed by dividing the Net Profit After Tax available for Equity Shareholders by the weighted average number of equity shares, after giving dilutive effect of the outstanding Warrants, Stock Options and Convertible bonds for the respective periods. Since, the effect of the conversion of Preference shares was anti-dilutive, it has been ignored.		
	<u>Continuing operations</u>		
	Net profit / (loss) for the year from continuing operations	36.51	134.36
	Less: Preference dividend and tax thereon	-	-
	Net profit / (loss) for the year attributable to the equity shareholders from continuing operations	36.51	134.36
	Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
	Profit / (loss) attributable to equity shareholders from continuing operations (on dilution)	36.51	134.36
	Weighted average number of equity shares for Basic EPS	10,000.00	10,000.00
	Add: Effect of warrants, ESOPs and Convertible bonds which are dilutive	-	-
	Weighted average number of equity shares - for diluted EPS	10,000.00	10,000.00
	Par value per share	10.00	10.00
	Earnings per share, from continuing operations - Diluted	365.12	1,343.62

